FierceBiotech Feb 26, 2026 Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies
FierceBiotech Feb 26, 2026 Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial
FierceBiotech Feb 26, 2026 Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases
FierceBiotech Feb 26, 2026 Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial
FierceBiotech Feb 26, 2026 Quantum Surgical snaps up J&J's NeuWave Medical for its microwave ablation technology
FierceBiotech Feb 26, 2026 Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits
FierceBiotech Feb 26, 2026 Accent halts solid tumor trial over adverse events, pivots to other lead cancer program
FierceBiotech Feb 25, 2026 Worried Trump's MFN push will ‘destroy biotech innovation,’ midsize companies form coalition to fight back
FierceBiotech Feb 25, 2026 Charles River sells manufacturing and discovery businesses to fulfill promised pivot
FierceBiotech Feb 25, 2026 Novo Nordisk inks $2.1B pact with Langer startup to boost oral drug delivery prowess
FierceBiotech Feb 25, 2026 After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
FierceBiotech Feb 25, 2026 GSK pays $950M in cash for Canadian biotech and its Winrevair-like blood pressure drug
FierceBiotech Feb 25, 2026 After 230% deal size explosion, China is no longer the 'bargain basement' for biopharma licensing: analyst
FierceBiotech Feb 24, 2026 Evinova reels in AI clinical development deals with Astellas and AstraZeneca